You are here

  • Home
  • Archive
  • Volume 19, Issue 1
  • Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE

Article Text

Article menu
Download PDFPDF
Aetiology
Commentary
Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE
  1. Timothy K Liem,
  2. Thomas G DeLoughery
  1. Divisions of Vascular Surgery, Hematology/Oncology, and Laboratory Medicine, Oregon Health & Science University, Portland, Oregon, USA
  1. Correspondence to : Dr Timothy K Liem, Division of Vascular Surgery OP-11, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA; liemt{at}ohsu.edu

http://dx.doi.org/10.1136/eb-2013-101317

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709–718. RE-MEDY and RE-SONATE trials.OpenUrlCrossRefPubMedWeb of Science

    Context

    In patients with idiopathic deep vein thrombosis (DVT) or pulmonary embolism (PE), extending the duration of warfarin beyond the initial 3–6 months of anticoagulation significantly reduces the risk for recurrence.1 ,2 Dabigatran is an oral direct-thrombin inhibitor that has been shown to be as effective as warfarin in the first 6 months after a venous thromboembolism (VTE).3 However, its efficacy and safety for extended therapy is not known.

    Methods

    Two parallel double-blinded randomised controlled studies were conducted, evaluating extended therapy with …

    View Full Text

    Footnotes

    • Competing interests None.